Outlook Therapeutics (NASDAQ:OTLK) Issues Quarterly Earnings Results

Outlook Therapeutics (NASDAQ:OTLK) posted its earnings results on Friday. The company reported ($0.77) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.06, Zacks reports.

Outlook Therapeutics Stock Performance

NASDAQ OTLK opened at $2.01 on Friday. The firm’s fifty day moving average is $3.81 and its two-hundred day moving average is $5.90. The firm has a market cap of $47.55 million, a PE ratio of -0.19 and a beta of 0.46. Outlook Therapeutics has a one year low of $0.87 and a one year high of $12.85.

Wall Street Analyst Weigh In

OTLK has been the topic of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Outlook Therapeutics in a research report on Friday, November 29th. Ascendiant Capital Markets decreased their price objective on Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd. Chardan Capital restated a “neutral” rating on shares of Outlook Therapeutics in a research note on Monday, December 2nd. Finally, BTIG Research lowered their price target on shares of Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating for the company in a report on Friday, November 29th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $32.73.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.